Literature DB >> 23055435

Hypoxia-inducible factors as key regulators of tumor inflammation.

Soulafa Mamlouk1, Ben Wielockx.   

Abstract

Low levels of oxygen or hypoxia is often an obstacle in health, particularly in pathological disorders like cancer. The main family of transcription factors responsible for cell survival and adaptation under strenuous conditions of hypoxia are the "hypoxia-inducible factors" (HIFs). Together with prolyl hydroxylase domain enzymes (PHDs), HIFs regulates tumor angiogenesis, proliferation, invasion, metastasis, in addition to resistance to radiation and chemotherapy. Additionally, the entire HIF transcription cascade is involved in the "seventh" hallmark of cancer; inflammation. Studies have shown that hypoxia can influence tumor associated immune cells toward assisting in tumor proliferation, differentiation, vessel growth, distant metastasis and suppression of the immune response via cytokine expression alterations. These changes are not necessarily analogous to HIF's role in non-cancer immune responses, where hypoxia often encourages a strong inflammatory response.
Copyright © 2012 UICC.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23055435     DOI: 10.1002/ijc.27901

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  29 in total

1.  Activities of multiple cancer-related pathways are associated with BRAF mutation and predict the resistance to BRAF/MEK inhibitors in melanoma cells.

Authors:  Dingxie Liu; Xuan Liu; Mingzhao Xing
Journal:  Cell Cycle       Date:  2013-10-29       Impact factor: 4.534

Review 2.  HIF-1 at the crossroads of hypoxia, inflammation, and cancer.

Authors:  Kuppusamy Balamurugan
Journal:  Int J Cancer       Date:  2015-04-07       Impact factor: 7.396

Review 3.  Fighting the force: Potential of homeobox genes for tumor microenvironment regulation.

Authors:  Josette M Northcott; Jason J Northey; J Matthew Barnes; Valerie M Weaver
Journal:  Biochim Biophys Acta       Date:  2015-03-24

4.  VPA inhibits renal cancer cell migration by targeting HDAC2 and down-regulating HIF-1α.

Authors:  Feng-qiang Yang; Min Liu; Feng-ping Yang; Jianping Che; Wei Li; Wei Zhai; Guang-chun Wang; Jun-hua Zheng; Xi Li
Journal:  Mol Biol Rep       Date:  2014-01-05       Impact factor: 2.316

Review 5.  Unboxing the molecular modalities of mutagens in cancer.

Authors:  Smita Kumari; Sudhanshu Sharma; Dia Advani; Akanksha Khosla; Pravir Kumar; Rashmi K Ambasta
Journal:  Environ Sci Pollut Res Int       Date:  2021-10-05       Impact factor: 5.190

Review 6.  Nitric Oxide Synthase-2-Derived Nitric Oxide Drives Multiple Pathways of Breast Cancer Progression.

Authors:  Debashree Basudhar; Veena Somasundaram; Graciele Almeida de Oliveira; Aparna Kesarwala; Julie L Heinecke; Robert Y Cheng; Sharon A Glynn; Stefan Ambs; David A Wink; Lisa A Ridnour
Journal:  Antioxid Redox Signal       Date:  2016-09-07       Impact factor: 8.401

7.  Hypoxia and hypoxia-inducible factor 1 repress SEMA4B expression to promote non-small cell lung cancer invasion.

Authors:  Hong Jian; Bin Liu; Jie Zhang
Journal:  Tumour Biol       Date:  2014-01-29

8.  Tumor microenvironment-based feed-forward regulation of NOS2 in breast cancer progression.

Authors:  Julie L Heinecke; Lisa A Ridnour; Robert Y S Cheng; Christopher H Switzer; Michael M Lizardo; Chand Khanna; Sharon A Glynn; S Perwez Hussain; Howard A Young; Stefan Ambs; David A Wink
Journal:  Proc Natl Acad Sci U S A       Date:  2014-04-14       Impact factor: 11.205

Review 9.  Hypoxia-inducible factors in regulation of immune responses in tumour microenvironment.

Authors:  Vinit Kumar; Dmitry I Gabrilovich
Journal:  Immunology       Date:  2014-12       Impact factor: 7.397

10.  HIF-1A and C/EBPs transcriptionally regulate adipogenic differentiation of bone marrow-derived MSCs in hypoxia.

Authors:  Chen Jiang; Jun Sun; Yafei Dai; Pengfei Cao; Liyang Zhang; Shuping Peng; Yanhong Zhou; Guiyuan Li; Jingqun Tang; Juanjuan Xiang
Journal:  Stem Cell Res Ther       Date:  2015-03-12       Impact factor: 6.832

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.